Want to see ARVN full AI Analyst Report?
ARVN Stock Chart & Stats
$9.60
-$0.09(-1.11%)
At close: 4:00 PM EDT
$9.60
-$0.09(-1.11%)
Day’s Range― - ―
52-Week Range$6.97 - $14.51
Previous Close$8.04
Volume385.67K
Average Volume (3M)798.66K
Market Cap
$608.75M
Enterprise Value-$13.73
Total Cash (Recent Filing)$567.90M
Total Debt (Recent Filing)$8.20M
Price to Earnings (P/E)49.4
Beta1.34
Next Earnings
Nov 10, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding65,386,190
10 Day Avg. Volume594,339
30 Day Avg. Volume798,659
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.96Price Target Upside55.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$296.93M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Low LeverageSubstantial liquidity and negligible debt provide flexibility to fund clinical development through multiple upcoming milestones, reducing near-term dependence on external financing while preserving strategic options.
First PROTAC Approval And Partnered CommercializationThe first approved PROTAC validates Arvinas’s core technology and transfers commercialization responsibilities to a partner, creating potential milestone and royalty income while reducing Arvinas’s direct commercial burden.
Diversified Pipeline With Advancing Clinical CatalystsMultiple oncology and neurology programs create several opportunities for value creation rather than reliance on one asset. Advancing clinical data can improve partnership prospects and provide evidence for the broader degrader platform.
Bears Say
Persistent Operating Cash BurnThe company continues to consume substantial cash while funding research and development, and earnings have not translated into cash generation. Continued burn could reduce flexibility or require financing if milestones and partnerships do not offset spending.
Revenue Quality Remains Partnership-dependentCurrent revenue does not yet demonstrate durable recurring product sales, because collaboration accounting and milestone timing drove much of the recent increase. Future results may therefore remain volatile until partnered or internal products generate repeatable commercial revenue.
Clinical Execution And Leadership Transition RisksDelayed studies, initially sub-efficacious ARV-393 cohorts and a pending chief medical officer replacement increase execution risk. These issues may slow evidence generation, complicate clinical oversight and postpone potential value inflection points.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $6.97 and its highest was $14.51 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $608.75M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Nov 10, 2026 which is in 66 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Aug 04, 2026. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $2.954.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.87.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 65,386,190 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of $2.58 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went up 11.663%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.96 (55.88% Upside)
$14.96 (55.88% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 46.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $66.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
ARVN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major strategic and scientific milestones — notably the first PROTAC approval (VEPPANU), substantial one-time revenue recognition and continued advancement of multiple clinical and preclinical programs with clear near-term data catalysts. Arvinas has strengthened focus on Phase I oncology and neurology assets, reported meaningful cost reductions and maintained a cash runway into H2 2028. Offsetting these positives are execution and timing challenges: ARV-393 enrollment was slowed by conservative starting doses (yielding mostly sub-efficacious cohort data in 2026), ARV-102 experienced regulatory delays pushing patient trials into 2027, cash declined ~17% YoY, and recent revenue was materially driven by one-time licensing and milestone events. Overall, the call leans positive because substantive strategic wins, upcoming clinical catalysts and a solid balance sheet (despite the cash decline) outweigh the program-specific delays and one-time accounting impacts.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$14.96
▲(55.88% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.62% Insiders
19.04% Mutual Funds
21.66% Other Institutional Investors
40.64% Public Companies and
Individual Investors